Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Abbott Illinois

U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2Improvements were participant-led, using real-time glucose readings to guide everyday decisionsComplementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population3View original content:https://www.prnewswire.co.uk/news-releases/landmark-study-shows-libre-technology-helps-people-with-type-2-diabetes-on-basal-insulin-improve-glucose-management-302711833.html